120 related articles for article (PubMed ID: 27514505)
21. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
[TBL] [Abstract][Full Text] [Related]
22. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
[TBL] [Abstract][Full Text] [Related]
23. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
24. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
[TBL] [Abstract][Full Text] [Related]
26. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
Danesh NM; Lavaee P; Ramezani M; Abnous K; Taghdisi SM
Int J Pharm; 2015 Jul; 489(1-2):311-7. PubMed ID: 25936625
[TBL] [Abstract][Full Text] [Related]
27. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
28. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
29. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles.
Kim JH; Yeom JH; Ko JJ; Han MS; Lee K; Na SY; Bae J
J Biotechnol; 2011 Sep; 155(3):287-92. PubMed ID: 21807040
[TBL] [Abstract][Full Text] [Related]
30. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Papageorgiou I; Loken MR; Brodersen LE; Gbadamosi M; Uy GL; Meshinchi S; Lamba JK
Leuk Lymphoma; 2019 Sep; 60(9):2287-2290. PubMed ID: 30721105
[No Abstract] [Full Text] [Related]
31. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
32. [A clinical and laboratory study on acute myeloid leukemia with t(6;9)(p23;q34)].
Wang Y; Xue Y; Chen S; Wu Y; Pan J; Zhang J; Shen J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):34-7. PubMed ID: 20140864
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
[TBL] [Abstract][Full Text] [Related]
34. [Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression].
Matsui H; Takeshita A; Naito K; Onishi K; Ono R
Rinsho Ketsueki; 2002 May; 43(5):309-15. PubMed ID: 12096475
[No Abstract] [Full Text] [Related]
35. Residual normal, highly proliferative progenitors can be isolated from the CD34+/33- fraction of AML with a more differentiated phenotype (CD33+).
Raymakers R; Wittebol S; Pennings A; Linders E; Poddighe P; De Witte T
Leukemia; 1995 Mar; 9(3):450-7. PubMed ID: 7533867
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
37. CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia.
Juncà J; Garcia O; Garcia-Caro M; Vila J; Zamora L; Cabezón M; Alonso E; de la Banda E; Rodríguez-Hernández I; Ribera JM; Millá F
Ann Hematol; 2016 Dec; 95(12):1949-1954. PubMed ID: 27595757
[TBL] [Abstract][Full Text] [Related]
38. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
Oyan AM; Bø TH; Jonassen I; Ulvestad E; Gjertsen BT; Kalland KH; Bruserud O
Cytometry B Clin Cytom; 2005 Mar; 64(1):18-27. PubMed ID: 15668952
[TBL] [Abstract][Full Text] [Related]
39. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
[TBL] [Abstract][Full Text] [Related]
40. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
